EGFR NSCLC
Combination of Osimertinib and Chemotherapy Enhances Brain Control in Advanced EGFR-Mutated Lung Cancer: Results from FLAURA2 Trial
Anika Sharma
ESMO: LBA68 EGFR mutations are found in 10%-15% of non-small cell lung cancer (NSCLC) cases among European and Caucasian populations. ...
Rybrevant Redefines First-Line Care for Patients with EGFR Exon 20 Insertion Mutation (ESMO 2023)
Anika Sharma
ESMO 2023: LBA5 Targeted therapies have revolutionized the treatment of EGFR-mutant NSCLC in the last 20 years. However, EGFR exon ...
Tagrisso-chemo combo delays EGFR NSCLC progression by 9 months in first-line (IASLC WCLC 2023 Conference)
Anika Sharma
Against the formidable challenge of non-small cell lung cancer (NSCLC), AstraZeneca’s Tagrisso (osimertinib), when partnered with chemotherapy, has unveiled remarkable ...
